Global Non-Replicating mRNA Vaccine Market Growth 2025-2031
The global Non-Replicating mRNA Vaccine market size is predicted to grow from US$ 1451 million in 2025 to US$ 2012 million in 2031; it is expected to grow at a CAGR of 5.6% from 2025 to 2031.
A Non-Replicating mRNA Vaccine is a vaccine based on messenger RNA (mRNA) technology, characterized by the use of mRNA that does not replicate within the recipient's body. This vaccine delivers mRNA encoding specific antigens (such as proteins on the surface of viruses) to human cells, prompting them to produce protein fragments of these antigens. This, in turn, stimulates the immune system to generate an immune response against these antigens, such as antibody production and T-cell activation. Due to its non-replicating nature, the vaccine is highly safe and does not cause infection or disease. Non-Replicating mRNA Vaccines have been widely used in the COVID-19 pandemic, demonstrating their advantages of rapid development, efficient production, and easy distribution.
United States market for Non-Replicating mRNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Non-Replicating mRNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Non-Replicating mRNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Non-Replicating mRNA Vaccine players cover Pfizer, Moderna, Curevac, GSK, BioNTech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Non-Replicating mRNA Vaccine Industry Forecast” looks at past sales and reviews total world Non-Replicating mRNA Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-Replicating mRNA Vaccine sales for 2025 through 2031. With Non-Replicating mRNA Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Replicating mRNA Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Non-Replicating mRNA Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Replicating mRNA Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Replicating mRNA Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Replicating mRNA Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Replicating mRNA Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Replicating mRNA Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Non-Replicating mRNA Vaccine market?
What factors are driving Non-Replicating mRNA Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-Replicating mRNA Vaccine market opportunities vary by end market size?
How does Non-Replicating mRNA Vaccine break out by Type, by Application?
A Non-Replicating mRNA Vaccine is a vaccine based on messenger RNA (mRNA) technology, characterized by the use of mRNA that does not replicate within the recipient's body. This vaccine delivers mRNA encoding specific antigens (such as proteins on the surface of viruses) to human cells, prompting them to produce protein fragments of these antigens. This, in turn, stimulates the immune system to generate an immune response against these antigens, such as antibody production and T-cell activation. Due to its non-replicating nature, the vaccine is highly safe and does not cause infection or disease. Non-Replicating mRNA Vaccines have been widely used in the COVID-19 pandemic, demonstrating their advantages of rapid development, efficient production, and easy distribution.
United States market for Non-Replicating mRNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Non-Replicating mRNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Non-Replicating mRNA Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Non-Replicating mRNA Vaccine players cover Pfizer, Moderna, Curevac, GSK, BioNTech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Non-Replicating mRNA Vaccine Industry Forecast” looks at past sales and reviews total world Non-Replicating mRNA Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-Replicating mRNA Vaccine sales for 2025 through 2031. With Non-Replicating mRNA Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Replicating mRNA Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Non-Replicating mRNA Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Replicating mRNA Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Replicating mRNA Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Replicating mRNA Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Replicating mRNA Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Replicating mRNA Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Cancer Non-Replicating mRNA Vaccine
- Infectious Diseases Non-Replicating mRNA Vaccine
- Others
- Hospital
- Clinic
- CDC
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Moderna
- Curevac
- GSK
- BioNTech
- CSPC
- Walvax
- Abogen
- AIM Vaccine
- Sanofi
What is the 10-year outlook for the global Non-Replicating mRNA Vaccine market?
What factors are driving Non-Replicating mRNA Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-Replicating mRNA Vaccine market opportunities vary by end market size?
How does Non-Replicating mRNA Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-Replicating mRNA Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Non-Replicating mRNA Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Non-Replicating mRNA Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Non-Replicating mRNA Vaccine Segment by Type
2.2.1 Cancer Non-Replicating mRNA Vaccine
2.2.2 Infectious Diseases Non-Replicating mRNA Vaccine
2.2.3 Others
2.3 Non-Replicating mRNA Vaccine Sales by Type
2.3.1 Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Non-Replicating mRNA Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Non-Replicating mRNA Vaccine Sale Price by Type (2020-2025)
2.4 Non-Replicating mRNA Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 CDC
2.4.4 Others
2.5 Non-Replicating mRNA Vaccine Sales by Application
2.5.1 Global Non-Replicating mRNA Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Non-Replicating mRNA Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Non-Replicating mRNA Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Non-Replicating mRNA Vaccine Breakdown Data by Company
3.1.1 Global Non-Replicating mRNA Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Non-Replicating mRNA Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Non-Replicating mRNA Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Non-Replicating mRNA Vaccine Revenue by Company (2020-2025)
3.2.2 Global Non-Replicating mRNA Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Non-Replicating mRNA Vaccine Sale Price by Company
3.4 Key Manufacturers Non-Replicating mRNA Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-Replicating mRNA Vaccine Product Location Distribution
3.4.2 Players Non-Replicating mRNA Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NON-REPLICATING MRNA VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Non-Replicating mRNA Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Non-Replicating mRNA Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Non-Replicating mRNA Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Non-Replicating mRNA Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Non-Replicating mRNA Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Non-Replicating mRNA Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Non-Replicating mRNA Vaccine Sales Growth
4.4 APAC Non-Replicating mRNA Vaccine Sales Growth
4.5 Europe Non-Replicating mRNA Vaccine Sales Growth
4.6 Middle East & Africa Non-Replicating mRNA Vaccine Sales Growth
5 AMERICAS
5.1 Americas Non-Replicating mRNA Vaccine Sales by Country
5.1.1 Americas Non-Replicating mRNA Vaccine Sales by Country (2020-2025)
5.1.2 Americas Non-Replicating mRNA Vaccine Revenue by Country (2020-2025)
5.2 Americas Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
5.3 Americas Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Replicating mRNA Vaccine Sales by Region
6.1.1 APAC Non-Replicating mRNA Vaccine Sales by Region (2020-2025)
6.1.2 APAC Non-Replicating mRNA Vaccine Revenue by Region (2020-2025)
6.2 APAC Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
6.3 APAC Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-Replicating mRNA Vaccine by Country
7.1.1 Europe Non-Replicating mRNA Vaccine Sales by Country (2020-2025)
7.1.2 Europe Non-Replicating mRNA Vaccine Revenue by Country (2020-2025)
7.2 Europe Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
7.3 Europe Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-Replicating mRNA Vaccine by Country
8.1.1 Middle East & Africa Non-Replicating mRNA Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Non-Replicating mRNA Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-Replicating mRNA Vaccine
10.3 Manufacturing Process Analysis of Non-Replicating mRNA Vaccine
10.4 Industry Chain Structure of Non-Replicating mRNA Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-Replicating mRNA Vaccine Distributors
11.3 Non-Replicating mRNA Vaccine Customer
12 WORLD FORECAST REVIEW FOR NON-REPLICATING MRNA VACCINE BY GEOGRAPHIC REGION
12.1 Global Non-Replicating mRNA Vaccine Market Size Forecast by Region
12.1.1 Global Non-Replicating mRNA Vaccine Forecast by Region (2026-2031)
12.1.2 Global Non-Replicating mRNA Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Non-Replicating mRNA Vaccine Forecast by Type (2026-2031)
12.7 Global Non-Replicating mRNA Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Moderna
13.2.1 Moderna Company Information
13.2.2 Moderna Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.2.3 Moderna Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Moderna Main Business Overview
13.2.5 Moderna Latest Developments
13.3 Curevac
13.3.1 Curevac Company Information
13.3.2 Curevac Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.3.3 Curevac Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Curevac Main Business Overview
13.3.5 Curevac Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.4.3 GSK Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 BioNTech
13.5.1 BioNTech Company Information
13.5.2 BioNTech Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.5.3 BioNTech Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 BioNTech Main Business Overview
13.5.5 BioNTech Latest Developments
13.6 CSPC
13.6.1 CSPC Company Information
13.6.2 CSPC Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.6.3 CSPC Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 CSPC Main Business Overview
13.6.5 CSPC Latest Developments
13.7 Walvax
13.7.1 Walvax Company Information
13.7.2 Walvax Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.7.3 Walvax Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Walvax Main Business Overview
13.7.5 Walvax Latest Developments
13.8 Abogen
13.8.1 Abogen Company Information
13.8.2 Abogen Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.8.3 Abogen Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Abogen Main Business Overview
13.8.5 Abogen Latest Developments
13.9 AIM Vaccine
13.9.1 AIM Vaccine Company Information
13.9.2 AIM Vaccine Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.9.3 AIM Vaccine Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 AIM Vaccine Main Business Overview
13.9.5 AIM Vaccine Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.10.3 Sanofi Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-Replicating mRNA Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Non-Replicating mRNA Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Non-Replicating mRNA Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Non-Replicating mRNA Vaccine Segment by Type
2.2.1 Cancer Non-Replicating mRNA Vaccine
2.2.2 Infectious Diseases Non-Replicating mRNA Vaccine
2.2.3 Others
2.3 Non-Replicating mRNA Vaccine Sales by Type
2.3.1 Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Non-Replicating mRNA Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Non-Replicating mRNA Vaccine Sale Price by Type (2020-2025)
2.4 Non-Replicating mRNA Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 CDC
2.4.4 Others
2.5 Non-Replicating mRNA Vaccine Sales by Application
2.5.1 Global Non-Replicating mRNA Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Non-Replicating mRNA Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Non-Replicating mRNA Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Non-Replicating mRNA Vaccine Breakdown Data by Company
3.1.1 Global Non-Replicating mRNA Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Non-Replicating mRNA Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Non-Replicating mRNA Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Non-Replicating mRNA Vaccine Revenue by Company (2020-2025)
3.2.2 Global Non-Replicating mRNA Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Non-Replicating mRNA Vaccine Sale Price by Company
3.4 Key Manufacturers Non-Replicating mRNA Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-Replicating mRNA Vaccine Product Location Distribution
3.4.2 Players Non-Replicating mRNA Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NON-REPLICATING MRNA VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Non-Replicating mRNA Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Non-Replicating mRNA Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Non-Replicating mRNA Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Non-Replicating mRNA Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Non-Replicating mRNA Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Non-Replicating mRNA Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Non-Replicating mRNA Vaccine Sales Growth
4.4 APAC Non-Replicating mRNA Vaccine Sales Growth
4.5 Europe Non-Replicating mRNA Vaccine Sales Growth
4.6 Middle East & Africa Non-Replicating mRNA Vaccine Sales Growth
5 AMERICAS
5.1 Americas Non-Replicating mRNA Vaccine Sales by Country
5.1.1 Americas Non-Replicating mRNA Vaccine Sales by Country (2020-2025)
5.1.2 Americas Non-Replicating mRNA Vaccine Revenue by Country (2020-2025)
5.2 Americas Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
5.3 Americas Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Replicating mRNA Vaccine Sales by Region
6.1.1 APAC Non-Replicating mRNA Vaccine Sales by Region (2020-2025)
6.1.2 APAC Non-Replicating mRNA Vaccine Revenue by Region (2020-2025)
6.2 APAC Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
6.3 APAC Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-Replicating mRNA Vaccine by Country
7.1.1 Europe Non-Replicating mRNA Vaccine Sales by Country (2020-2025)
7.1.2 Europe Non-Replicating mRNA Vaccine Revenue by Country (2020-2025)
7.2 Europe Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
7.3 Europe Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-Replicating mRNA Vaccine by Country
8.1.1 Middle East & Africa Non-Replicating mRNA Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Non-Replicating mRNA Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Non-Replicating mRNA Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Non-Replicating mRNA Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-Replicating mRNA Vaccine
10.3 Manufacturing Process Analysis of Non-Replicating mRNA Vaccine
10.4 Industry Chain Structure of Non-Replicating mRNA Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-Replicating mRNA Vaccine Distributors
11.3 Non-Replicating mRNA Vaccine Customer
12 WORLD FORECAST REVIEW FOR NON-REPLICATING MRNA VACCINE BY GEOGRAPHIC REGION
12.1 Global Non-Replicating mRNA Vaccine Market Size Forecast by Region
12.1.1 Global Non-Replicating mRNA Vaccine Forecast by Region (2026-2031)
12.1.2 Global Non-Replicating mRNA Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Non-Replicating mRNA Vaccine Forecast by Type (2026-2031)
12.7 Global Non-Replicating mRNA Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Moderna
13.2.1 Moderna Company Information
13.2.2 Moderna Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.2.3 Moderna Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Moderna Main Business Overview
13.2.5 Moderna Latest Developments
13.3 Curevac
13.3.1 Curevac Company Information
13.3.2 Curevac Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.3.3 Curevac Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Curevac Main Business Overview
13.3.5 Curevac Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.4.3 GSK Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 BioNTech
13.5.1 BioNTech Company Information
13.5.2 BioNTech Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.5.3 BioNTech Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 BioNTech Main Business Overview
13.5.5 BioNTech Latest Developments
13.6 CSPC
13.6.1 CSPC Company Information
13.6.2 CSPC Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.6.3 CSPC Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 CSPC Main Business Overview
13.6.5 CSPC Latest Developments
13.7 Walvax
13.7.1 Walvax Company Information
13.7.2 Walvax Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.7.3 Walvax Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Walvax Main Business Overview
13.7.5 Walvax Latest Developments
13.8 Abogen
13.8.1 Abogen Company Information
13.8.2 Abogen Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.8.3 Abogen Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Abogen Main Business Overview
13.8.5 Abogen Latest Developments
13.9 AIM Vaccine
13.9.1 AIM Vaccine Company Information
13.9.2 AIM Vaccine Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.9.3 AIM Vaccine Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 AIM Vaccine Main Business Overview
13.9.5 AIM Vaccine Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Non-Replicating mRNA Vaccine Product Portfolios and Specifications
13.10.3 Sanofi Non-Replicating mRNA Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-Replicating mRNA Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Non-Replicating mRNA Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Cancer Non-Replicating mRNA Vaccine
Table 4. Major Players of Infectious Diseases Non-Replicating mRNA Vaccine
Table 5. Major Players of Others
Table 6. Global Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 7. Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Table 8. Global Non-Replicating mRNA Vaccine Revenue by Type (2020-2025) & ($ million)
Table 9. Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2020-2025)
Table 10. Global Non-Replicating mRNA Vaccine Sale Price by Type (2020-2025) & (US$/Unit)
Table 11. Global Non-Replicating mRNA Vaccine Sale by Application (2020-2025) & (K Units)
Table 12. Global Non-Replicating mRNA Vaccine Sale Market Share by Application (2020-2025)
Table 13. Global Non-Replicating mRNA Vaccine Revenue by Application (2020-2025) & ($ million)
Table 14. Global Non-Replicating mRNA Vaccine Revenue Market Share by Application (2020-2025)
Table 15. Global Non-Replicating mRNA Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Non-Replicating mRNA Vaccine Sales by Company (2020-2025) & (K Units)
Table 17. Global Non-Replicating mRNA Vaccine Sales Market Share by Company (2020-2025)
Table 18. Global Non-Replicating mRNA Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Non-Replicating mRNA Vaccine Revenue Market Share by Company (2020-2025)
Table 20. Global Non-Replicating mRNA Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Non-Replicating mRNA Vaccine Producing Area Distribution and Sales Area
Table 22. Players Non-Replicating mRNA Vaccine Products Offered
Table 23. Non-Replicating mRNA Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Non-Replicating mRNA Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Non-Replicating mRNA Vaccine Sales Market Share Geographic Region (2020-2025)
Table 28. Global Non-Replicating mRNA Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Non-Replicating mRNA Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Non-Replicating mRNA Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Non-Replicating mRNA Vaccine Sales Market Share by Country/Region (2020-2025)
Table 32. Global Non-Replicating mRNA Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Non-Replicating mRNA Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)
Table 35. Americas Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2025)
Table 36. Americas Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 38. Americas Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 39. APAC Non-Replicating mRNA Vaccine Sales by Region (2020-2025) & (K Units)
Table 40. APAC Non-Replicating mRNA Vaccine Sales Market Share by Region (2020-2025)
Table 41. APAC Non-Replicating mRNA Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 43. APAC Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 44. Europe Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)
Table 45. Europe Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 47. Europe Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Non-Replicating mRNA Vaccine
Table 53. Key Market Challenges & Risks of Non-Replicating mRNA Vaccine
Table 54. Key Industry Trends of Non-Replicating mRNA Vaccine
Table 55. Non-Replicating mRNA Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Non-Replicating mRNA Vaccine Distributors List
Table 58. Non-Replicating mRNA Vaccine Customer List
Table 59. Global Non-Replicating mRNA Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Non-Replicating mRNA Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Non-Replicating mRNA Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Non-Replicating mRNA Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Non-Replicating mRNA Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Non-Replicating mRNA Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Non-Replicating mRNA Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Non-Replicating mRNA Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Non-Replicating mRNA Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Non-Replicating mRNA Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Non-Replicating mRNA Vaccine Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Non-Replicating mRNA Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Non-Replicating mRNA Vaccine Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Non-Replicating mRNA Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Pfizer Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 75. Pfizer Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Moderna Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Moderna Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 80. Moderna Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Moderna Main Business
Table 82. Moderna Latest Developments
Table 83. Curevac Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Curevac Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 85. Curevac Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Curevac Main Business
Table 87. Curevac Latest Developments
Table 88. GSK Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. GSK Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 90. GSK Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. GSK Main Business
Table 92. GSK Latest Developments
Table 93. BioNTech Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. BioNTech Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 95. BioNTech Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. BioNTech Main Business
Table 97. BioNTech Latest Developments
Table 98. CSPC Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. CSPC Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 100. CSPC Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. CSPC Main Business
Table 102. CSPC Latest Developments
Table 103. Walvax Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Walvax Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 105. Walvax Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Walvax Main Business
Table 107. Walvax Latest Developments
Table 108. Abogen Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Abogen Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 110. Abogen Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Abogen Main Business
Table 112. Abogen Latest Developments
Table 113. AIM Vaccine Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. AIM Vaccine Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 115. AIM Vaccine Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. AIM Vaccine Main Business
Table 117. AIM Vaccine Latest Developments
Table 118. Sanofi Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Sanofi Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 120. Sanofi Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. Sanofi Main Business
Table 122. Sanofi Latest Developments
Table 1. Non-Replicating mRNA Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Non-Replicating mRNA Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Cancer Non-Replicating mRNA Vaccine
Table 4. Major Players of Infectious Diseases Non-Replicating mRNA Vaccine
Table 5. Major Players of Others
Table 6. Global Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 7. Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Table 8. Global Non-Replicating mRNA Vaccine Revenue by Type (2020-2025) & ($ million)
Table 9. Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2020-2025)
Table 10. Global Non-Replicating mRNA Vaccine Sale Price by Type (2020-2025) & (US$/Unit)
Table 11. Global Non-Replicating mRNA Vaccine Sale by Application (2020-2025) & (K Units)
Table 12. Global Non-Replicating mRNA Vaccine Sale Market Share by Application (2020-2025)
Table 13. Global Non-Replicating mRNA Vaccine Revenue by Application (2020-2025) & ($ million)
Table 14. Global Non-Replicating mRNA Vaccine Revenue Market Share by Application (2020-2025)
Table 15. Global Non-Replicating mRNA Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Non-Replicating mRNA Vaccine Sales by Company (2020-2025) & (K Units)
Table 17. Global Non-Replicating mRNA Vaccine Sales Market Share by Company (2020-2025)
Table 18. Global Non-Replicating mRNA Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Non-Replicating mRNA Vaccine Revenue Market Share by Company (2020-2025)
Table 20. Global Non-Replicating mRNA Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Non-Replicating mRNA Vaccine Producing Area Distribution and Sales Area
Table 22. Players Non-Replicating mRNA Vaccine Products Offered
Table 23. Non-Replicating mRNA Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Non-Replicating mRNA Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Non-Replicating mRNA Vaccine Sales Market Share Geographic Region (2020-2025)
Table 28. Global Non-Replicating mRNA Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Non-Replicating mRNA Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Non-Replicating mRNA Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Non-Replicating mRNA Vaccine Sales Market Share by Country/Region (2020-2025)
Table 32. Global Non-Replicating mRNA Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Non-Replicating mRNA Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)
Table 35. Americas Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2025)
Table 36. Americas Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 38. Americas Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 39. APAC Non-Replicating mRNA Vaccine Sales by Region (2020-2025) & (K Units)
Table 40. APAC Non-Replicating mRNA Vaccine Sales Market Share by Region (2020-2025)
Table 41. APAC Non-Replicating mRNA Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 43. APAC Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 44. Europe Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)
Table 45. Europe Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 47. Europe Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Non-Replicating mRNA Vaccine Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Non-Replicating mRNA Vaccine Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Non-Replicating mRNA Vaccine
Table 53. Key Market Challenges & Risks of Non-Replicating mRNA Vaccine
Table 54. Key Industry Trends of Non-Replicating mRNA Vaccine
Table 55. Non-Replicating mRNA Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Non-Replicating mRNA Vaccine Distributors List
Table 58. Non-Replicating mRNA Vaccine Customer List
Table 59. Global Non-Replicating mRNA Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Non-Replicating mRNA Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Non-Replicating mRNA Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Non-Replicating mRNA Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Non-Replicating mRNA Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Non-Replicating mRNA Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Non-Replicating mRNA Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Non-Replicating mRNA Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Non-Replicating mRNA Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Non-Replicating mRNA Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Non-Replicating mRNA Vaccine Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Non-Replicating mRNA Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Non-Replicating mRNA Vaccine Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Non-Replicating mRNA Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Pfizer Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 75. Pfizer Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Moderna Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Moderna Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 80. Moderna Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Moderna Main Business
Table 82. Moderna Latest Developments
Table 83. Curevac Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Curevac Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 85. Curevac Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Curevac Main Business
Table 87. Curevac Latest Developments
Table 88. GSK Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. GSK Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 90. GSK Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. GSK Main Business
Table 92. GSK Latest Developments
Table 93. BioNTech Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. BioNTech Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 95. BioNTech Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. BioNTech Main Business
Table 97. BioNTech Latest Developments
Table 98. CSPC Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. CSPC Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 100. CSPC Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. CSPC Main Business
Table 102. CSPC Latest Developments
Table 103. Walvax Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Walvax Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 105. Walvax Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Walvax Main Business
Table 107. Walvax Latest Developments
Table 108. Abogen Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Abogen Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 110. Abogen Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Abogen Main Business
Table 112. Abogen Latest Developments
Table 113. AIM Vaccine Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. AIM Vaccine Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 115. AIM Vaccine Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. AIM Vaccine Main Business
Table 117. AIM Vaccine Latest Developments
Table 118. Sanofi Basic Information, Non-Replicating mRNA Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Sanofi Non-Replicating mRNA Vaccine Product Portfolios and Specifications
Table 120. Sanofi Non-Replicating mRNA Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. Sanofi Main Business
Table 122. Sanofi Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non-Replicating mRNA Vaccine
Figure 2. Non-Replicating mRNA Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-Replicating mRNA Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Non-Replicating mRNA Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Non-Replicating mRNA Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Non-Replicating mRNA Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Non-Replicating mRNA Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Cancer Non-Replicating mRNA Vaccine
Figure 12. Product Picture of Infectious Diseases Non-Replicating mRNA Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Non-Replicating mRNA Vaccine Sales Market Share by Type in 2025
Figure 15. Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2020-2025)
Figure 16. Non-Replicating mRNA Vaccine Consumed in Hospital
Figure 17. Global Non-Replicating mRNA Vaccine Market: Hospital (2020-2025) & (K Units)
Figure 18. Non-Replicating mRNA Vaccine Consumed in Clinic
Figure 19. Global Non-Replicating mRNA Vaccine Market: Clinic (2020-2025) & (K Units)
Figure 20. Non-Replicating mRNA Vaccine Consumed in CDC
Figure 21. Global Non-Replicating mRNA Vaccine Market: CDC (2020-2025) & (K Units)
Figure 22. Non-Replicating mRNA Vaccine Consumed in Others
Figure 23. Global Non-Replicating mRNA Vaccine Market: Others (2020-2025) & (K Units)
Figure 24. Global Non-Replicating mRNA Vaccine Sale Market Share by Application (2024)
Figure 25. Global Non-Replicating mRNA Vaccine Revenue Market Share by Application in 2025
Figure 26. Non-Replicating mRNA Vaccine Sales by Company in 2025 (K Units)
Figure 27. Global Non-Replicating mRNA Vaccine Sales Market Share by Company in 2025
Figure 28. Non-Replicating mRNA Vaccine Revenue by Company in 2025 ($ millions)
Figure 29. Global Non-Replicating mRNA Vaccine Revenue Market Share by Company in 2025
Figure 30. Global Non-Replicating mRNA Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Non-Replicating mRNA Vaccine Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 33. Americas Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 34. APAC Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 35. APAC Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 36. Europe Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 37. Europe Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 39. Middle East & Africa Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 40. Americas Non-Replicating mRNA Vaccine Sales Market Share by Country in 2025
Figure 41. Americas Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2025)
Figure 42. Americas Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 43. Americas Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 44. United States Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Non-Replicating mRNA Vaccine Sales Market Share by Region in 2025
Figure 49. APAC Non-Replicating mRNA Vaccine Revenue Market Share by Region (2020-2025)
Figure 50. APAC Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 51. APAC Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 52. China Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. India Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Non-Replicating mRNA Vaccine Sales Market Share by Country in 2025
Figure 60. Europe Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2025)
Figure 61. Europe Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 62. Europe Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 63. Germany Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. France Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 71. Egypt Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Non-Replicating mRNA Vaccine in 2025
Figure 77. Manufacturing Process Analysis of Non-Replicating mRNA Vaccine
Figure 78. Industry Chain Structure of Non-Replicating mRNA Vaccine
Figure 79. Channels of Distribution
Figure 80. Global Non-Replicating mRNA Vaccine Sales Market Forecast by Region (2026-2031)
Figure 81. Global Non-Replicating mRNA Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Non-Replicating mRNA Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Non-Replicating mRNA Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Non-Replicating mRNA Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Non-Replicating mRNA Vaccine Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Non-Replicating mRNA Vaccine
Figure 2. Non-Replicating mRNA Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-Replicating mRNA Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Non-Replicating mRNA Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Non-Replicating mRNA Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Non-Replicating mRNA Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Non-Replicating mRNA Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Cancer Non-Replicating mRNA Vaccine
Figure 12. Product Picture of Infectious Diseases Non-Replicating mRNA Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Non-Replicating mRNA Vaccine Sales Market Share by Type in 2025
Figure 15. Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2020-2025)
Figure 16. Non-Replicating mRNA Vaccine Consumed in Hospital
Figure 17. Global Non-Replicating mRNA Vaccine Market: Hospital (2020-2025) & (K Units)
Figure 18. Non-Replicating mRNA Vaccine Consumed in Clinic
Figure 19. Global Non-Replicating mRNA Vaccine Market: Clinic (2020-2025) & (K Units)
Figure 20. Non-Replicating mRNA Vaccine Consumed in CDC
Figure 21. Global Non-Replicating mRNA Vaccine Market: CDC (2020-2025) & (K Units)
Figure 22. Non-Replicating mRNA Vaccine Consumed in Others
Figure 23. Global Non-Replicating mRNA Vaccine Market: Others (2020-2025) & (K Units)
Figure 24. Global Non-Replicating mRNA Vaccine Sale Market Share by Application (2024)
Figure 25. Global Non-Replicating mRNA Vaccine Revenue Market Share by Application in 2025
Figure 26. Non-Replicating mRNA Vaccine Sales by Company in 2025 (K Units)
Figure 27. Global Non-Replicating mRNA Vaccine Sales Market Share by Company in 2025
Figure 28. Non-Replicating mRNA Vaccine Revenue by Company in 2025 ($ millions)
Figure 29. Global Non-Replicating mRNA Vaccine Revenue Market Share by Company in 2025
Figure 30. Global Non-Replicating mRNA Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Non-Replicating mRNA Vaccine Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 33. Americas Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 34. APAC Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 35. APAC Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 36. Europe Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 37. Europe Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Non-Replicating mRNA Vaccine Sales 2020-2025 (K Units)
Figure 39. Middle East & Africa Non-Replicating mRNA Vaccine Revenue 2020-2025 ($ millions)
Figure 40. Americas Non-Replicating mRNA Vaccine Sales Market Share by Country in 2025
Figure 41. Americas Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2025)
Figure 42. Americas Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 43. Americas Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 44. United States Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Non-Replicating mRNA Vaccine Sales Market Share by Region in 2025
Figure 49. APAC Non-Replicating mRNA Vaccine Revenue Market Share by Region (2020-2025)
Figure 50. APAC Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 51. APAC Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 52. China Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. India Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Non-Replicating mRNA Vaccine Sales Market Share by Country in 2025
Figure 60. Europe Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2025)
Figure 61. Europe Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 62. Europe Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 63. Germany Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. France Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)
Figure 71. Egypt Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Non-Replicating mRNA Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Non-Replicating mRNA Vaccine in 2025
Figure 77. Manufacturing Process Analysis of Non-Replicating mRNA Vaccine
Figure 78. Industry Chain Structure of Non-Replicating mRNA Vaccine
Figure 79. Channels of Distribution
Figure 80. Global Non-Replicating mRNA Vaccine Sales Market Forecast by Region (2026-2031)
Figure 81. Global Non-Replicating mRNA Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Non-Replicating mRNA Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Non-Replicating mRNA Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Non-Replicating mRNA Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Non-Replicating mRNA Vaccine Revenue Market Share Forecast by Application (2026-2031)